Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Nat Med 2019 01 26;25(1):111-118. Epub 2018 Nov 26.

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.

Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance and resistance, especially in the absence of preexisting subclones, remains unclear. In epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cells, we demonstrate that residual disease and acquired resistance in response to EGFR inhibitors requires Aurora kinase A (AURKA) activity. Nongenetic resistance through the activation of AURKA by its coactivator TPX2 emerges in response to chronic EGFR inhibition where it mitigates drug-induced apoptosis. Aurora kinase inhibitors suppress this adaptive survival program, increasing the magnitude and duration of EGFR inhibitor response in preclinical models. Treatment-induced activation of AURKA is associated with resistance to EGFR inhibitors in vitro, in vivo and in most individuals with EGFR-mutant lung adenocarcinoma. These findings delineate a molecular path whereby drug resistance emerges from drug-tolerant cells and unveils a synthetic lethal strategy for enhancing responses to EGFR inhibitors by suppressing AURKA-driven residual disease and acquired resistance.

Download full-text PDF

Source
http://www.nature.com/articles/s41591-018-0264-7
Publisher Site
http://dx.doi.org/10.1038/s41591-018-0264-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324945PMC
January 2019

Publication Analysis

Top Keywords

egfr inhibitors
16
acquired resistance
12
residual disease
12
aurora kinase
12
disease acquired
8
lung adenocarcinoma
8
egfr-mutant lung
8
activation aurka
8
resistance
8
egfr
6
inhibitors
5
cells demonstrate
4
associated resistance
4
increasing magnitude
4
suppress adaptive
4
demonstrate residual
4
adenocarcinoma cells
4
resistance response
4
inhibitors requires
4
findings delineate
4

Similar Publications